S Ogbourne - 2011 - espace.library.uq.edu.au Plasminogen activator inhibitor type 2 (PAI-2) is a serine protease inhibitor traditionally regarded as a regulator of fibrinolysis and extracellular matrix degradation. More recently, PAI-2 has been implicated in diverse processes such as keratinocyte differentiation, cell death and viral ... Cached - All 2 versions
I Kajiwara, H Soejima, S Miyamoto… - Thrombosis Research, 2011 - Elsevier Serotonin level was higher in patients with MVD than in those with SVD (p < 0.05) and in those with CPS (p < 0.001). The formation of small-sized platelet aggregates was significantly higher in the high serotonin group than in the low serotonin group of SEA patients. The formation ... Related articles - All 2 versions
M Sudol - Oncogene, 2011 - nature.com Plasminogen activator (PLAU) is a serine protease that converts plasminogen to plasmin, a general protease, which promotes fibrinolysis and degradation of extracellular matrix. PLAU was reported in 1970s as one of the robustly induced enzymatic activities in Rous sarcoma virus (RSV)- ... Related articles - All 3 versions
R Cancello, C Rouault, G Guilhem, JF Bedel… - Obesity …, 2011 - content.karger.com Objective: At present, circulating markers characterizing the inflammatory infiltration of white adipose tissue (WAT) in human obesity are not well known. We previously identified, by a pangenomic approach (microarrays), the urokinase plasminogen activator receptor (PLAUR or CD87) ... Cited by 1 - Related articles - All 2 versions
[PDF] from ulg.ac.beA Masset, C Maillard, NE Sounni… - … Journal of Cancer, 2011 - Wiley Online Library Angiogenesis, extracellular matrix remodeling and cell migration are associated with cancer progression and involve at least, the plasminogen activating system and its main physiological inhibitor, the plasminogen activator inhibitor-1 (PAI-1). Considering the recognized ... Cited by 1 - Related articles - All 5 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
